To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
137
Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Hydroxychloroquine administered as a loading dose only
Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Expo Covid Isolation Center / Mayo Hospital Field Hospital
Lahore, Punjab Province, Pakistan
Mayo Hospital / King Edward Medical University
Lahore, Punjab Province, Pakistan
Pakistan Kidney and Liver Institute
Lahore, Punjab Province, Pakistan
Services Hospital
Lahore, Punjab Province, Pakistan
RT-PCR result
Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Time frame: 6th and 7th day
Progression of symptoms
Time to progression to next stage of SARS-CoV-2 disease severity index
Time frame: 7 days
Mortality
Death
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Standard of Care plus placebo